Alzamend Neuro insider buys 108,388 ALZN shares

Alzamend Neuro, Inc. (ALZN) had an amended insider report from director Milton C. Ault III correcting previously omitted purchases on April 14, 2026.

Rhea-AI Filing Summary

Alzamend Neuro, Inc. (ALZN) had an amended insider report from director Milton C. Ault III correcting previously omitted purchases on April 14, 2026. An entity associated with him, Ault Lending, LLC, bought 108,388 shares of common stock at about $1.0047 per share, held indirectly, bringing that entity’s holdings to 116,648 shares. Ault also directly purchased 2,000 shares at a volume weighted average price of $1.0338 per share, with trading that day occurring between $1.00 and $1.05 per share. He is also reported to have indirect holdings of 11,068 shares through Ault Life Sciences, Inc. and 61 shares through Ault Life Sciences Fund, LLC.

Insider Trade Summary

Net Buyer: 110,388 shares

Net Buy 4 txns

Insider AULT MILTON C III

Role Director

Bought 110,388 shs ($111K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	108,388	$1.0047	$109K
Purchase	Common Stock F2	2,000	$1.0338	$2K
holding	Common Stock F3	--	--	--
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 116,648 shares (Indirect, By Ault Lending, LLC); Common Stock — 2,000 shares (Direct); Common Stock — 11,068 shares (Indirect, By Ault Life Sciences, Inc.); Common Stock — 61 shares (Indirect, By Ault Life Sciences Fund, LLC)

Footnotes (4)

1. F1. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
2. F2. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.0338. The range of purchase prices on the transaction date was $1.00 to $1.05 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
3. F3. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
4. F4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

Key Figures

Indirect shares purchased via Ault Lending, LLC: 108,388 shares of Common Stock Purchase price per share via Ault Lending, LLC: $1.0047 per share Indirect holdings via Ault Lending, LLC after transaction: 116,648 shares of Common Stock +5 more

8 metrics

Indirect shares purchased via Ault Lending, LLC 108,388 shares of Common Stock Purchased on April 14, 2026

Purchase price per share via Ault Lending, LLC $1.0047 per share Purchase of 108,388 shares on April 14, 2026

Indirect holdings via Ault Lending, LLC after transaction 116,648 shares of Common Stock Reported total after April 14, 2026 purchase

Direct shares purchased 2,000 shares of Common Stock Purchased on April 14, 2026

Volume weighted average purchase price (direct) $1.0338 per share Direct open market purchases on April 14, 2026

Trading price range on transaction date $1.00 to $1.05 per share Range for common stock purchases on April 14, 2026

Indirect holdings via Ault Life Sciences, Inc. 11,068 shares of Common Stock Reported as of April 14, 2026

Indirect holdings via Ault Life Sciences Fund, LLC 61 shares of Common Stock Reported as of April 14, 2026

Key Terms

indirect, volume weighted average purchase price, open market transactions, voting and investment power, +1 more

5 terms

indirect financial

"direct_or_indirect: "I" indicates indirect ownership through entities"

volume weighted average purchase price financial

"with a volume weighted average purchase price of $1.0338"

The volume weighted average purchase price is the average price an investor paid for a security, calculated by giving more weight to prices where more shares were bought—so large trades move the average more than small ones. Investors use it like a cost-basis yardstick to see whether current market prices are above or below what they effectively paid, helping judge gains, losses, and whether to sell or add to a position.

open market transactions financial

"common stock was purchased by the reporting person in open market transactions"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

voting and investment power financial

"is deemed to have voting and investment power with respect to the securities"

held of record financial

"securities held of record by Ault Lending"

FAQ

What insider transactions did Milton C. Ault III report in the amended Form 4 for ALZN?

He reported additional purchases on April 14, 2026: 108,388 ALZN common shares indirectly via Ault Lending, LLC at about $1.0047 per share and 2,000 shares purchased directly at a volume weighted average price of $1.0338 per share.

How many ALZN shares did Ault Lending, LLC hold after the April 14, 2026 purchase?

After the reported April 14, 2026 purchase, Ault Lending, LLC held 116,648 shares of Alzamend Neuro, Inc. common stock, over which Milton C. Ault III is deemed to have voting and investment power according to the filing’s footnote.

What direct ALZN share position did Milton C. Ault III report after the amended transactions?

He reported directly holding 2,000 shares of Alzamend Neuro, Inc. common stock after his April 14, 2026 open market purchases at a volume weighted average price of $1.0338 per share, with trades in a range of $1.00–$1.05 per share.

What additional indirect ALZN holdings are associated with Milton C. Ault III?

He is reported to have sole voting and investment power over 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC, both positions reported as indirect ownership of Alzamend Neuro, Inc. common stock.

Why was this Form 4/A amendment filed for ALZN?

The amendment states it was filed solely to add shares of common stock purchased by the reporting person that were inadvertently omitted from the original April 16, 2026 Form 4. No other previously reported transactions or holdings were changed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 06:57 AM Accepted by SEC EDGAR 08/31/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AULT MILTON C III

(Last) (First) (Middle)

11411 SOUTHERN HIGHLANDS PARKWAY

SUITE 190

(Street)

LAS VEGAS NEVADA 89141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ ALZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		P		108,388	A	$1.0047	116,648	I	By Ault Lending, LLC(1)
Common Stock	04/14/2026		P		2,000	A	$1.0338(2)	2,000	D
Common Stock								11,068	I	By Ault Life Sciences, Inc.(3)
Common Stock								61	I	By Ault Life Sciences Fund, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

2. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.0338. The range of purchase prices on the transaction date was $1.00 to $1.05 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

3. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

Remarks:

The original Form 4 filed on April 16, 2026 (the "Original Filing") is amended by this Form 4/A solely to report shares of common stock purchased by the reporting person that were inadvertently omitted from the Original Filing. Other than the correction reflected herein, no changes have been made to the transactions or holdings previously reported in the Original Filing.

	/s/ Milton C. Ault, III	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)